Norman Delaney

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4288854/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genomic analysis of "microphenotypes―in epilepsy. American Journal of Medical Genetics, Part A, 2022, 188, 138-146.	1.2	3
2	Hypoglycaemic events resembling focal seizures -A case report and literature review. Seizure: the Journal of the British Epilepsy Association, 2022, 94, 10-17.	2.0	4
3	Whole exome sequencing studies in epilepsy: A deep analysis of the published literature. American Journal of Medical Genetics, Part A, 2022, , .	1.2	0
4	A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam. Epilepsia, 2022, 63, 1563-1570.	5.1	11
5	Electrochemiluminescent detection of epilepsy biomarker miR-134 using a metal complex light switch. Bioelectrochemistry, 2022, 146, 108150.	4.6	1
6	Eventâ€based modeling in temporal lobe epilepsy demonstrates progressive atrophy from crossâ€sectional data. Epilepsia, 2022, 63, 2081-2095.	5.1	11
7	<scp>MicroRNA</scp> inhibition using <scp>antimiRs</scp> in acute human brain tissue sections. Epilepsia, 2022, 63, .	5.1	5
8	Acetazolamide: Old drug, new evidence?. Epilepsia Open, 2022, 7, 378-392.	2.4	13
9	Coproducing health and well-being in partnership with patients, families, and healthcare providers: A qualitative study exploring the role of an epilepsy patient portal. Epilepsy and Behavior, 2021, 115, 107664.	1.7	6
10	LoVE in a time of CoVID: Clinician and patient experience using telemedicine for chronic epilepsy management. Epilepsy and Behavior, 2021, 115, 107675.	1.7	27
11	Evaluating risk to people with epilepsy during the COVID-19 pandemic: Preliminary findings from the COV-E study. Epilepsy and Behavior, 2021, 115, 107658.	1.7	37
12	Elevated blood purine levels as a biomarker of seizures and epilepsy. Epilepsia, 2021, 62, 817-828.	5.1	21
13	Diverse genetic causes of polymicrogyria with epilepsy. Epilepsia, 2021, 62, 973-983.	5.1	12
14	Assessing the role of rare genetic variants in drugâ€resistant, nonâ€lesional focal epilepsy. Annals of Clinical and Translational Neurology, 2021, 8, 1376-1387.	3.7	16
15	Precision therapy in the genetic epilepsies of childhood. Developmental Medicine and Child Neurology, 2021, 63, 1276-1282.	2.1	9
16	Role of Common Genetic Variants for Drug-Resistance to Specific Anti-Seizure Medications. Frontiers in Pharmacology, 2021, 12, 688386.	3.5	6
17	Predictors of seizure freedom, response and retention after 12 months of treatment with eslicarbazepine acetate: A post-hoc analysis of the Euro-Esli study. Epilepsy Research, 2021, 174, 106653.	1.6	2
18	Democratizing epilepsy care: Utility and usability of an electronic patient portal. Epilepsy and Behavior, 2021, 122, 108197.	1.7	3

#	Article	IF	CITATIONS
19	Epilepsy in the mTORopathies: opportunities for precision medicine. Brain Communications, 2021, 3, fcab222.	3.3	53
20	Stick or twist: Everolimus for seizures in tuberous sclerosis complex during the COVID-19 pandemic. Seizure: the Journal of the British Epilepsy Association, 2021, 91, 271-272.	2.0	1
21	Impact of the COVID-19 pandemic on people with epilepsy: Findings from the Brazilian arm of the COV-E study. Epilepsy and Behavior, 2021, 123, 108261.	1.7	8
22	Reversible male infertility with valproate use: A review of the literature. Epilepsy and Behavior Reports, 2021, 16, 100446.	1.0	14
23	Exploring the genetic overlap between psychiatric illness and epilepsy: A review. Epilepsy and Behavior, 2020, 102, 106669.	1.7	12
24	The development of an epilepsy electronic patient portal: Facilitating both patient empowerment and remote clinicianâ€patient interaction in a postâ€COVIDâ€19 world. Epilepsia, 2020, 61, 1894-1905.	5.1	26
25	Testing association of rare genetic variants with resistance to three common antiseizure medications. Epilepsia, 2020, 61, 657-666.	5.1	22
26	Could the 2017 ILAE and the four-dimensional epilepsy classifications be merged to a new "Integrated Epilepsy Classification�. Seizure: the Journal of the British Epilepsy Association, 2020, 78, 31-37.	2.0	18
27	A comparison of genomic diagnostics in adults and children with epilepsy and comorbid intellectual disability. European Journal of Human Genetics, 2020, 28, 1066-1077.	2.8	30
28	De-novo mutations in patients with chronic ultra-refractory epilepsy with onset after age five years. European Journal of Medical Genetics, 2020, 63, 103625.	1.3	9
29	Tackling Epilepsy With High-definition Precision Medicine. JAMA Neurology, 2019, 76, 1109.	9.0	53
30	Ultra-Rare Genetic Variation in the Epilepsies: A Whole-Exome Sequencing Study of 17,606 Individuals. American Journal of Human Genetics, 2019, 105, 267-282.	6.2	237
31	Development of a genomics module within an epilepsyâ€specific electronic health record: Toward genomic medicine in epilepsy care. Epilepsia, 2019, 60, 1670-1677.	5.1	7
32	Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy. Epilepsia Open, 2019, 4, 420-430.	2.4	34
33	Genomic and clinical predictors of lacosamide response in refractory epilepsies. Epilepsia Open, 2019, 4, 563-571.	2.4	12
34	Eslicarbazepine acetate as monotherapy in clinical practice: Outcomes from Euro-Esli. Acta Neurologica Scandinavica, 2019, 139, 49-63.	2.1	7
35	Normal cerebral cortical thickness in first-degree relatives of temporal lobe epilepsy patients. Neurology, 2019, 92, e351-e358.	1.1	7
36	Elevation of plasma tRNA fragments precedes seizures in human epilepsy. Journal of Clinical Investigation, 2019, 129, 2946-2951.	8.2	71

#	Article	IF	CITATIONS
37	Genetic variation in <i>CFH</i> predicts phenytoin-induced maculopapular exanthema in European-descent patients. Neurology, 2018, 90, e332-e341.	1.1	43
38	Dual-center, dual-platform microRNA profiling identifies potential plasma biomarkers of adult temporal lobe epilepsy. EBioMedicine, 2018, 38, 127-141.	6.1	88
39	The phenotype of bilateral hippocampal sclerosis and its management in "real life―clinical settings. Epilepsia, 2018, 59, 1410-1420.	5.1	6
40	Genomics-Guided Precise Anti-Epileptic Drug Development. Neurochemical Research, 2017, 42, 2084-2088.	3.3	9
41	Potent Anti-seizure Effects of Locked Nucleic Acid Antagomirs Targeting miR-134 in Multiple Mouse and Rat Models of Epilepsy. Molecular Therapy - Nucleic Acids, 2017, 6, 45-56.	5.1	62
42	Comparative effectiveness of antiepileptic drugs in patients with mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsia, 2017, 58, 1734-1741.	5.1	26
43	The spectrum of peri-ictal MRI changes; four illustrative cases. Seizure: the Journal of the British Epilepsy Association, 2017, 50, 189-193.	2.0	11
44	eHealth as a Facilitator of Precision Medicine in Epilepsy. Biomedicine Hub, 2017, 2, 1-9.	1.2	2
45	Current practices in long-term video-EEG monitoring services: A survey among partners of the E-PILEPSY pilot network of reference for refractory epilepsy and epilepsy surgery. Seizure: the Journal of the British Epilepsy Association, 2016, 38, 38-45.	2.0	67
46	Clinical experience with adjunctive perampanel in adult patients with uncontrolled epilepsy: A UK and Ireland multicentre study. Seizure: the Journal of the British Epilepsy Association, 2016, 34, 1-5.	2.0	56
47	Temporal Cortex Morphology in Mesial Temporal Lobe Epilepsy Patients and Their Asymptomatic Siblings. Cerebral Cortex, 2016, 26, 1234-1241.	2.9	32
48	Genome-wide Polygenic Burden of Rare Deleterious Variants in Sudden Unexpected Death in Epilepsy. EBioMedicine, 2015, 2, 1063-1070.	6.1	74
49	White matter alterations in patients with <scp>MRI</scp> â€negative temporal lobe epilepsy and their asymptomatic siblings. Epilepsia, 2015, 56, 1551-1561.	5.1	34
50	Postoperative AED Management – Not So Clear Cut. Epilepsy Currents, 2015, 15, 120-121.	0.8	0
51	Direct, non-amplified detection of microRNA-134 in plasma from epilepsy patients. RSC Advances, 2015, 5, 90071-90078.	3.6	15
52	Psychiatric and neuropsychological profiles of people with psychogenic nonepileptic seizures. Epilepsy and Behavior, 2015, 43, 39-45.	1.7	41
53	Common genetic variants influence human subcortical brain structures. Nature, 2015, 520, 224-229.	27.8	772
54	Complex Detection, Complex Decisions: More Detail on Subclinical Seizures in the Acutely Sick Brain. Epilepsy Currents, 2014, 14, 129-130.	0.8	3

#	Article	IF	CITATIONS
55	Two Further Blood Pressure Loci Identified in Ion Channel Genes With a Genecentric Approach. Circulation: Cardiovascular Genetics, 2014, 7, 873-879.	5.1	7
56	TDP2 protects transcription from abortive topoisomerase activity and is required for normal neural function. Nature Genetics, 2014, 46, 516-521.	21.4	122
57	The consequences of refractory epilepsy and its treatment. Epilepsy and Behavior, 2014, 37, 59-70.	1.7	482
58	De Novo Mutations in Synaptic Transmission Genes Including DNM1 Cause Epileptic Encephalopathies. American Journal of Human Genetics, 2014, 95, 360-370.	6.2	388
59	Weight change, genetics and antiepileptic drugs. Expert Review of Clinical Pharmacology, 2014, 7, 43-51.	3.1	26
60	De novo mutations in epileptic encephalopathies. Nature, 2013, 501, 217-221.	27.8	1,351
61	Diagnostic Exome Sequencing: A New Paradigm in Neurology. Neuron, 2013, 80, 841-843.	8.1	15
62	MRIâ€Based Brain Structure Volumes in Temporal Lobe Epilepsy Patients and their Unaffected Siblings: A Preliminary Study. Journal of Neuroimaging, 2013, 23, 64-70.	2.0	14
63	Assessing the quality of epilepsy care with an electronic patient record. Seizure: the Journal of the British Epilepsy Association, 2013, 22, 604-610.	2.0	32
64	Levetiracetam in pregnancy. Neurology, 2013, 80, 400-405.	1.1	148
65	CHOP regulates the p53–MDM2 axis and is required for neuronal survival after seizures. Brain, 2013, 136, 577-592.	7.6	95
66	Epilepsy, hippocampal sclerosis and febrile seizures linked by common genetic variation around SCN1A. Brain, 2013, 136, 3140-3150.	7.6	168
67	Regional increase of cerebral cortex thickness in juvenile myoclonic epilepsy. Epilepsia, 2013, 54, e138-41.	5.1	31
68	Herpes simplex virus encephalitis involving the right thalamus. BMJ Case Reports, 2013, 2013, bcr2013010206-bcr2013010206.	0.5	10
69	Heritability of Subcortical Volumetric Traits in Mesial Temporal Lobe Epilepsy. PLoS ONE, 2013, 8, e61880.	2.5	16
70	Psychogenic Nonepileptic Seizures. Archives of Neurology, 2012, 69, 1349.	4.5	22
71	Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions. Pharmacogenomics, 2012, 13, 399-405.	1.3	38
72	Opportunities and Challenges for Genome Sequencing in the Clinic. Advances in Protein Chemistry and Structural Biology, 2012, 89, 65-83.	2.3	9

#	Article	IF	CITATIONS
73	Complex single gene disorders and epilepsy. Epilepsia, 2012, 53, 81-91.	5.1	26
74	Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects. Nature Medicine, 2012, 18, 1087-1094.	30.7	423
75	Identification of common variants associated with human hippocampal and intracranial volumes. Nature Genetics, 2012, 44, 552-561.	21.4	594
76	A comparison of propofol and amobarbital for use in the Wada test. Seizure: the Journal of the British Epilepsy Association, 2012, 21, 399-401.	2.0	12
77	Evidence-based models of care for people with epilepsy. Epilepsy and Behavior, 2012, 23, 1-6.	1.7	41
78	Exome Sequencing Followed by Large-Scale Genotyping Fails to Identify Single Rare Variants of Large Effect in Idiopathic Generalized Epilepsy. American Journal of Human Genetics, 2012, 91, 293-302.	6.2	95
79	Status of memory loss. BMJ Case Reports, 2012, 2012, bcr1120115267-bcr1120115267.	0.5	1
80	Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: Open″abel, noncomparative, multicenter, longâ€ŧerm followâ€up study. Epilepsia, 2012, 53, 111-119.	5.1	39
81	A cross-sectional MRI study of brain regional atrophy and clinical characteristics of temporal lobe epilepsy with hippocampal sclerosis. Epilepsy Research, 2012, 99, 156-166.	1.6	29
82	Widespread cortical morphologic changes in juvenile myoclonic epilepsy: Evidence from structural MRI. Epilepsia, 2012, 53, 651-658.	5.1	61
83	Asymmetric cortical surface area and morphology changes in mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsia, 2012, 53, 995-1003.	5.1	31
84	Reduced Mature MicroRNA Levels in Association with Dicer Loss in Human Temporal Lobe Epilepsy with Hippocampal Sclerosis. PLoS ONE, 2012, 7, e35921.	2.5	121
85	HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans. New England Journal of Medicine, 2011, 364, 1134-1143.	27.0	815
86	Regulation or Rising Cream?. Epilepsy Currents, 2011, 11, 82-83.	0.8	0
87	Cortical curvature analysis in MRI-negative temporal lobe epilepsy: A surrogate marker for malformations of cortical development. Epilepsia, 2011, 52, 28-34.	5.1	13
88	Genomic microdeletions associated with epilepsy: Not a contraindication to resective surgery. Epilepsia, 2011, 52, 1388-1392.	5.1	16
89	Pharmacogenomics and epilepsy: the road ahead. Pharmacogenomics, 2011, 12, 1429-1447.	1.3	31
90	Rare Deletions at 16p13.11 Predispose to a Diverse Spectrum of Sporadic Epilepsy Syndromes. American Journal of Human Genetics, 2010, 86, 707-718.	6.2	231

#	Article	IF	CITATIONS
91	Formative evaluation of a telemedicine model for delivering clinical neurophysiology services part I: Utility, technical performance and service provider perspective. BMC Medical Informatics and Decision Making, 2010, 10, 48.	3.0	16
92	Socio-technical considerations in epilepsy electronic patient record implementation. International Journal of Medical Informatics, 2010, 79, 349-360.	3.3	16
93	Examining the prevalence of epilepsy and delivery of epilepsy care in Ireland. Epilepsia, 2010, 51, 845-852.	5.1	46
94	Neuroanatomical correlates of psychosis in temporal lobe epilepsy: voxel-based morphometry study. British Journal of Psychiatry, 2010, 197, 482-492.	2.8	33
95	Common genetic variation and susceptibility to partial epilepsies: a genome-wide association study. Brain, 2010, 133, 2136-2147.	7.6	132
96	Epilepsy in Ireland: Towards the primary–tertiary care continuum. Seizure: the Journal of the British Epilepsy Association, 2010, 19, 47-52.	2.0	14
97	The Irish epilepsy surgery experience: Long-term follow-up. Seizure: the Journal of the British Epilepsy Association, 2010, 19, 247-252.	2.0	23
98	Lafora Disease. CNS Drugs, 2010, 24, 549-561.	5.9	158
99	<i>MDR1/ABCB1</i> polymorphisms and multidrug resistance in epilepsy: in and out of fashion. Pharmacogenomics, 2009, 10, 711-713.	1.3	22
100	Hypophysitis secondary to ruptured Rathke's cyst mimicking neurosarcoidosis. Journal of Clinical Neuroscience, 2009, 16, 599-600.	1.5	9
101	Psychogenic non-epileptic seizures in an Irish tertiary referral centre for epilepsy. Irish Journal of Psychological Medicine, 2009, 26, 174-178.	1.0	4
102	An assessment of the Irish population for large-scale genetic mapping studies involving epilepsy and other complex diseases. European Journal of Human Genetics, 2008, 16, 176-183.	2.8	5
103	Chapter 2 Epidemiology and Classification of Epilepsy. International Review of Neurobiology, 2008, 83, 11-26.	2.0	121
104	The alcohol withdrawal syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 854-862.	1.9	214
105	ANTIEPILEPTIC DRUG INTERACTIONS. CONTINUUM Lifelong Learning in Neurology, 2007, 13, 91-105.	0.8	5
106	The controversial association of ABCB1 polymorphisms in refractory epilepsy: An analysis of multiple SNPs in an Irish population. Epilepsy Research, 2007, 73, 192-198.	1.6	63
107	Cerebral Cortical Gyrification: A Preliminary Investigation in Temporal Lobe Epilepsy. Epilepsia, 2007, 48, 211-219.	5.1	27
108	Outcome Measurement after Vagal Nerve Stimulation Therapy: Proposal of a New Classification. Epilepsia, 2007, 48, 375-378.	5.1	109

#	Article	IF	CITATIONS
109	A Multicenter Study of BRD2 as a Risk Factor for Juvenile Myoclonic Epilepsy. Epilepsia, 2007, 48, 706-712.	5.1	76
110	Sleep deprivation: A clinical perspective. Sleep and Biological Rhythms, 2007, 5, 2-14.	1.0	11
111	Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case-control study. Lancet Neurology, The, 2007, 6, 970-980.	10.2	175
112	Alcohol-related seizures. Journal of Emergency Medicine, 2006, 31, 157-163.	0.7	73
113	Vigabatrin Retinopathy in an Irish Cohort: Lack of Correlation with Dose. Epilepsia, 2006, 47, 311-317.	5.1	44
114	A pharmacogenetic exploration of vigabatrin-induced visual field constriction. Epilepsy Research, 2006, 70, 144-152.	1.6	26
115	Examining the role of common genetic variation in the γ2 subunit of the GABAA receptor in epilepsy using tagging SNPs. Epilepsy Research, 2006, 70, 229-238.	1.6	17
116	Quantitative MRI: a reliable protocol for measurement of cerebral gyrification using stereology. Magnetic Resonance Imaging, 2006, 24, 265-272.	1.8	28
117	Use of complementary and alternative medicine in epilepsy. Current Neurology and Neuroscience Reports, 2006, 6, 347-353.	4.2	42
118	Seizure versus syncope. Lancet Neurology, The, 2006, 5, 171-180.	10.2	137
119	Broadening the Phenotype of Childhood-Onset Dopa-Responsive Dystonia. Archives of Neurology, 2006, 63, 1185.	4.5	33
120	Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. Lancet Neurology, The, 2005, 4, 239-248.	10.2	243
121	Oxidative injury in epilepsy: potential for antioxidant therapy?. Expert Review of Neurotherapeutics, 2004, 4, 541-553.	2.8	53
122	Hodgkins disease presenting with granulomatous angiitis of the central nervous system. Journal of Neurology, 2003, 250, 112-113.	3.6	18
123	Herbal Remedies, Dietary Supplements, andâ€∫Seizures. Epilepsia, 2003, 44, 228-235.	5.1	84
124	Statin therapy and stroke prevention. Current Opinion in Cardiology, 2001, 16, 219-224.	1.8	39
125	Patients' Aims for Epilepsy Surgery: Desires Beyond Seizure Freedom. Epilepsia, 2001, 42, 629-633.	5.1	107
126	Statins and neuroprotection. Expert Opinion on Investigational Drugs, 2001, 10, 1847-1853.	4.1	29

#	Article	IF	CITATIONS
127	Primary generalized epilepsies. Current Treatment Options in Neurology, 2000, 2, 527-541.	1.8	22
128	Oxidative injury in diseases of the central nervous system: focus on alzheimer's disease. American Journal of Medicine, 2000, 109, 577-585.	1.5	349
129	A Randomized, Placebo-Controlled, Crossover Study of E5510 and Aspirin in Healthy Volunteers. Journal of Cardiovascular Pharmacology, 1999, 33, 12-18.	1.9	7
130	Medical causes of seizures. Lancet, The, 1998, 352, 383-390.	13.7	158
131	Treatment of Lennox-Gastaut Syndrome. CNS Drugs, 1998, 10, 181-188.	5.9	16